Vorolanib - Tyrogenex

Drug Profile

Vorolanib - Tyrogenex

Alternative Names: CM-082; X-82

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tyrogenex
  • Developer AnewPharma; Tyrogenex; Washington University School of Medicine; Xcovery Holdings
  • Class Antineoplastics; Eye disorder therapies; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Renal cell carcinoma
  • Phase II Age-related macular degeneration; Solid tumours; Wet age-related macular degeneration
  • Phase I/II Pancreatic cancer

Most Recent Events

  • 27 Jul 2018 AnewPharma plans a phase II trial for Melanoma (Combination therapy) in July 2018 (NCT03602547)
  • 11 Jul 2018 Xcovery Holdings in collaboration with Bristol-Myers Squibb plans a phase I/II trial for Non-small Cell Lung Cancer and Malignant-thymoma in USA , (NCT03583086)
  • 01 Jun 2018 Phase-II development in Wet age-related macular degeneration and Solid tumours is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top